KdT Ventures

KdT Ventures is an early-stage venture capital firm based in Austin, Texas. Founded in 2017 by Cain McClary, they specialize in investing in startups in the data, engineering, and biology sectors, along with healthcare technology systems, pharmaceuticals, biotechnology, agriculture, chemicals, gases, and life sciences. KdT Ventures aims to support founders in re-architecting the world at a molecular level, establishing themselves as a standard in science venture investing.

Rima Chakrabarti

Principal

Phil Grayeski Ph.D

Principal

Mack Healy

Managing Partner

Benji Leibowitz

Associate

Patrick Malone

Principal

Cain McClary

Managing Partner and Founder

Ketan Yerneni

Principal

81 past transactions

PathAI

Series C in 2021
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Marigold Health

Seed Round in 2022
Marigold Health uses AI-augmented chat support groups to reach and retain patients with behavioral health needs in community-based treatment. Patients receive a personalized wraparound support while care teams see dramatic gains in capacity using patients to engage each other. We partner directly with treatment providers and managed care organizations in the Medicaid market.

PathAI

Series A in 2017
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Hi Fidelity Genetics

Series A in 2018
Hi Fidelity Genetics LLC develops hardware and software for plant-breeding applications. It offers tools to measure and predict plant traits. The tools help for maintaining a sufficient supply of food as the world's population grows and its climate changes. The company is headquartered in Durham, North Carolina.

Debut

Seed Round in 2020
Debut Biotechnology, Inc. provides biomanufacturing solutions for high value molecules. It offers biomanufacturing cartridges, fermentation, immobilization of cells and enzymes, and new enzymes for pharmaceutical production and modification. The company also creates novel immobilization for enzymes with high success rates; and provides high value immobilized enzymes for use in continuous manufacturing systems. It serves pharmaceutical and specialty chemical industries. Debut Biotechnology, Inc. was incorporated in 2019 and is based in San Diego, California.

Onc.AI

Venture Round in 2020
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

Canaery

Seed Round in 2022
Canaery is building a neural interface for analyzing an object’s scent fingerprint to identify dangerous compounds at places like ports and inspection points without (or in addition to) x-rays or cameras.

Abridge

Seed Round in 2018
Abridge is a brand and communication strategy firm that offers creative communication and event planning services to its clients. The company’s range of services include advertising, event planning, consultancy, publishing, and linguistic localization. Abridge was founded in 2011 by Simone Spreafico, Daniele Maggi, Gianluca Longo, and Ugo Cesare Tonelli and is based in Lombardia.

Modulus Therapeutics

Seed Round in 2021
Modulus Therapeutics is an artificial-intelligence-powered cell therapy design company.

Dyno Therapeutics

Series A in 2021
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Hi Fidelity Genetics

Private Placement in 2018
Hi Fidelity Genetics LLC develops hardware and software for plant-breeding applications. It offers tools to measure and predict plant traits. The tools help for maintaining a sufficient supply of food as the world's population grows and its climate changes. The company is headquartered in Durham, North Carolina.

SeQure DX

Venture Round in 2021
SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

Abridge

Series A in 2020
Abridge is a brand and communication strategy firm that offers creative communication and event planning services to its clients. The company’s range of services include advertising, event planning, consultancy, publishing, and linguistic localization. Abridge was founded in 2011 by Simone Spreafico, Daniele Maggi, Gianluca Longo, and Ugo Cesare Tonelli and is based in Lombardia.

Patchd Inc

Seed Round in 2018
Patchd Inc develops a wearable device with advanced computation to predict sepsis in the outpatient setting. The company’s wireless patch provides continuous vital sign data to doctors and facilitates earlier detection of life threatening illnesses when deployed by hospitals for newly admitted patients. Its sign monitoring patch and artificial intelligence based algorithms provides predictive healthcare. The company was incorporated in 2017 and is headquartered in San Francisco, California.

Circularis

Seed Round in 2020
Circularis Biotechnologies, Inc. develops a method to regulate gene expression and enable increased biotherapeutic production yields. The company develops RACRE Variant Libraries, hCMV Variant Library, Protein expression with CMV promoters, and T7 Variant Library. It provide services, including RACRE Enhancement, RACRE Discovery, RACRE Technology Access Program, and Ribozyme Analysis of Cis-Regulatory Elements. The company was founded in 2014 and is based in San Leandro, California.

Theator

Series A in 2021
Theator Inc. develops a personalized and artificial intelligence (AI) powered, surgeon growth video platform. The company offers Minutes, which is based on a real-world dataset and comprised of two general modules for surgeons, including content management software and a visual operative report with analytics. Further, it houses and analyzes video data from surgical procedures and is intended to be utilized by surgeons to review and analyze prior surgeries for educational purposes. Theator Inc. was incorporated in 2018 and is based in San Mateo, California.

Visla Labs

Seed Round in 2018
Visla Labs Inc. develops artificial intelligence based platform for radiology and healthcare industry. The company was incorporated in 2018 and is headquartered in San Francisco, California.

Xilis

Seed Round in 2020
Xilis, Inc. develops next generation organoid technologies to guide precision therapy for cancer patients and improve drug discovery. It offers The XilisµO, a platform that enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery. Xilis, Inc. was founded in 2019 and is based in Chapel Hill, North Carolina.

54gene

Seed Round in 2019
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Solugen

Series B in 2019
Solugen is a specialty chemicals ​manufacturer creating chemistries that are safe, cost-effective, and environmentally-friendly. The company manufactures and supplies of registered biocides and specialty bio-based solutions for divalent control in process flow assurance and asset integrity. Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with the competition.

Abridge

Seed Round in 2019
Abridge is a brand and communication strategy firm that offers creative communication and event planning services to its clients. The company’s range of services include advertising, event planning, consultancy, publishing, and linguistic localization. Abridge was founded in 2011 by Simone Spreafico, Daniele Maggi, Gianluca Longo, and Ugo Cesare Tonelli and is based in Lombardia.

Elemental Machines

Series A in 2018
Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency and consistency, and improved repeatability and gathers new data sets for advanced analytics.

Checkerspot

Series A in 2019
Checkerspot, Inc., a biotech company, produces performance materials using microalgae. The company was founded in 2016 and is based in Berkeley, California.

Unravel Biosciences

Seed Round in 2022
Unravel Biosciences develops a vertically integrated computational platform to improve drug discovery. Unravel’s platform screens many drugs in parallel for their real-world impact (e.g., the complete gene expression profiles and resulting physiological changes), reversing this process to identify the likely target(s) a drug is interacting with.

SURGE Therapeutics

Series B in 2023
SURGE Therapeutics seeks to dramatically improve cancer patient survival by disrupting cancer immunotherapy is deployed.

Dimension Inx

Series A in 2023
Dimension Inx Corp. designs and develops three dimensional (3D) printable material and 3D painted objects for research and commercial applications in the United States. The company provides products, such as Hyperelastic bone, 3D printable elastomeric and bioactive ceramic for bone regeneration; 3D graphene and graphite; fluffy-x, a solution for ultra-porous, mechanically elastic, soft tissue regeneration; tissue papers; and commercial medical devices. Dimension Inx Corp. was founded in 2016 and is based in Chicago, Illinois.

Asimov

Series B in 2023
Asimov, Inc. designs and develops genetically engineered therapeutics. It develops a genetic circuit’s platform for molecular manufacturing and therapeutic applications. The company develops machine-learning algorithms that bridge large-scale datasets with mechanistic models of biology. It manufactures protein biologics, viral vectors, cell, and gene therapy. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Equii

Seed Round in 2022
Equii is a food technology company that discovers highly nutritious sources of microbial proteins that are used to ferment grains and produce high-protein grain flours. Founded in 2021 by Monica Bhatia, Equii is based in San Ramon, California.

Azitra

Private Placement in 2018
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Tierra Biosciences

Private Placement in 2018
Tierra Biosciences develops cell free technologies that enables the discovery of molecules that are difficult to produce in common types of laboratory cells. The company’s technology uses automation, computation, and high throughput cell-free expression for expressing DNA from a variety of microbial sources. Tierra Biosciences’ Next Generation Expression platform allows for high-throughput data collection that is real and experimentally validated at speeds of simulation-based approaches. Tierra Biosciences was formerly known as Synvitrobio, Inc and changed its name to Tierra Biosciences in September 2018. Tierra Biosciences was founded in 2015 and is headquartered in San Francisco, California.

Terray Therapeutics

Series A in 2022
Terray Therapeutics, Inc. operates as a biotechnology company. The company develops treatments for intractable cause of human diseases. It engages in development of a screening platform for drug discovery and Platinum Technology, which is working on an electrode-like product for deep brain stimulation. The company was founded in 2018 and is based in Pasadena, California.

Rarebird

Seed Round in 2020
Revel Technologies, Inc. produces coffee that replaces caffeine. It offers Paraxanthine coffee that increases alertness without the jitters and anxiety for caffeine sensitive people. Revel Technologies, Inc. was founded in 2020 and is based in Oakland, California.

Debut

Private Placement in 2019
Debut Biotechnology, Inc. provides biomanufacturing solutions for high value molecules. It offers biomanufacturing cartridges, fermentation, immobilization of cells and enzymes, and new enzymes for pharmaceutical production and modification. The company also creates novel immobilization for enzymes with high success rates; and provides high value immobilized enzymes for use in continuous manufacturing systems. It serves pharmaceutical and specialty chemical industries. Debut Biotechnology, Inc. was incorporated in 2019 and is based in San Diego, California.

Dimension Inx

Venture Round in 2020
Dimension Inx Corp. designs and develops three dimensional (3D) printable material and 3D painted objects for research and commercial applications in the United States. The company provides products, such as Hyperelastic bone, 3D printable elastomeric and bioactive ceramic for bone regeneration; 3D graphene and graphite; fluffy-x, a solution for ultra-porous, mechanically elastic, soft tissue regeneration; tissue papers; and commercial medical devices. Dimension Inx Corp. was founded in 2016 and is based in Chicago, Illinois.

Theator

Seed Round in 2019
Theator Inc. develops a personalized and artificial intelligence (AI) powered, surgeon growth video platform. The company offers Minutes, which is based on a real-world dataset and comprised of two general modules for surgeons, including content management software and a visual operative report with analytics. Further, it houses and analyzes video data from surgical procedures and is intended to be utilized by surgeons to review and analyze prior surgeries for educational purposes. Theator Inc. was incorporated in 2018 and is based in San Mateo, California.

Zymochem

Seed Round in 2021
ZymoChem, Inc. develops microbes and bioprocesses that enable production of chemicals from renewable sources, such as sugars. The company was founded in 2013 and is based in Emeryville, California.

Rejuvenate Bio

Seed Round in 2018
Rejuvenate Bio Inc develops gene therapy which helps to increase the health and life spans of dogs and other domesticated animals. The company offers anti-aging therapies by adding new deoxyribo nucleic acid (DNA) instructions to their bodies. It also offers gene therapies directed at curing specific disease for pets. The company was founded in 2017 and is based in Brookline, Massachusetts.

Hi Fidelity Genetics

Series A in 2017
Hi Fidelity Genetics LLC develops hardware and software for plant-breeding applications. It offers tools to measure and predict plant traits. The tools help for maintaining a sufficient supply of food as the world's population grows and its climate changes. The company is headquartered in Durham, North Carolina.

Debut

Series A in 2021
Debut Biotechnology, Inc. provides biomanufacturing solutions for high value molecules. It offers biomanufacturing cartridges, fermentation, immobilization of cells and enzymes, and new enzymes for pharmaceutical production and modification. The company also creates novel immobilization for enzymes with high success rates; and provides high value immobilized enzymes for use in continuous manufacturing systems. It serves pharmaceutical and specialty chemical industries. Debut Biotechnology, Inc. was incorporated in 2019 and is based in San Diego, California.

Parthenon Therapeutics

Series A in 2021
Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks these barriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time.

PathAI

Private Placement in 2019
PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

Greeneye Technology

Series A in 2021
Green-Eye Technology develops an application for automated field scouting with a custom drone for sub-mm resolution. The company was founded in 2016 and is based in Canada.

Onc.AI

Private Placement in 2020
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

Azitra

Private Placement in 2019
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Debut

Series A in 2021
Debut Biotechnology, Inc. provides biomanufacturing solutions for high value molecules. It offers biomanufacturing cartridges, fermentation, immobilization of cells and enzymes, and new enzymes for pharmaceutical production and modification. The company also creates novel immobilization for enzymes with high success rates; and provides high value immobilized enzymes for use in continuous manufacturing systems. It serves pharmaceutical and specialty chemical industries. Debut Biotechnology, Inc. was incorporated in 2019 and is based in San Diego, California.

54gene

Series B in 2021
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Checkerspot

Seed Round in 2018
Checkerspot, Inc., a biotech company, produces performance materials using microalgae. The company was founded in 2016 and is based in Berkeley, California.

Solugen

Seed Round in 2017
Solugen is a specialty chemicals ​manufacturer creating chemistries that are safe, cost-effective, and environmentally-friendly. The company manufactures and supplies of registered biocides and specialty bio-based solutions for divalent control in process flow assurance and asset integrity. Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with the competition.

54gene

Private Placement in 2020
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Character Biosciences

Seed Round in 2020
Biopharmaceutical research and development company that's an affiliate of Clover Health

Theator

Private Placement in 2019
Theator Inc. develops a personalized and artificial intelligence (AI) powered, surgeon growth video platform. The company offers Minutes, which is based on a real-world dataset and comprised of two general modules for surgeons, including content management software and a visual operative report with analytics. Further, it houses and analyzes video data from surgical procedures and is intended to be utilized by surgeons to review and analyze prior surgeries for educational purposes. Theator Inc. was incorporated in 2018 and is based in San Mateo, California.

Azitra

Convertible Note in 2018
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Dyno Therapeutics

Seed Round in 2018
Dyno Therapeutics is pioneering an artificial intelligence (AI) powered approach to gene therapy. Using machine learning and quantitative high-throughput in vivo experimentation, we are inventing new ways to design gene vectors with a focus on cell-targeting capsid proteins from adeno-associated virus (AAV), the most widely-used vector for gene therapies.

Terray Therapeutics

Seed Round in 2019
Terray Therapeutics, Inc. operates as a biotechnology company. The company develops treatments for intractable cause of human diseases. It engages in development of a screening platform for drug discovery and Platinum Technology, which is working on an electrode-like product for deep brain stimulation. The company was founded in 2018 and is based in Pasadena, California.

Azitra

Private Placement in 2018
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Elemental Machines

Series A in 2018
Elemental Machines is revolutionizing science-based industries with a smart lab platform that offers powerful, data-driven insights to improve laboratory operations, research, development, and manufacturing outcomes. Continuously monitoring equipment and environmental variables provides new levels of clarity, transparency and consistency, and improved repeatability and gathers new data sets for advanced analytics.

54gene

Series A in 2020
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Zymochem

Series A in 2024
ZymoChem, Inc. develops microbes and bioprocesses that enable production of chemicals from renewable sources, such as sugars. The company was founded in 2013 and is based in Emeryville, California.

Aperiam Bio

Seed Round in 2023
Aperiam Bio partners with enzyme engineers and distributors to create and share stabilized, solubilized, and catalytically optimized proteins. The company was founded in 2021 and is headquartered in Austin, Texas, United States.

Elegen

Series B in 2024
Elegen is a biotechnology company that develops microfluidic technology. It is driven by a mission to deploy this technology in a new generation of DNA synthesizers aimed at enabling and accelerating biomedical advances. The company was founded in 2017 and led by Dr. Matthew Hill.

Remedy Robotics

Seed Round in 2020
Remedy Robotics develops robotic surgical devices to help in curing vascular diseases. It offers a device to automate the procedure of mechanical thrombectomy, thereby enabling medical staff to provide the treatment on time and patients to avoid severe post-stroke disabilities. The company was founded in 2020 and is based in San Francisco, California.

Onc.AI

Series A in 2023
Onc.AI is a software that specializes in clinical oncology, genomics, proteomics, and radiomics. The company develops a comprehensive approach to oncology diagnostics and uses deep learning to derive actionable insights into oncology treatment. It was founded in 2020 by Akshay Nanduri and Salmaan Ahmed and is based in San Carlos, California, United States.

54gene

Convertible Note in 2022
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Faeth

Series A in 2022
Faeth Therapeutics is a data-driven, evidence-based company that specializes in mechanistic understanding of the way that dietary nutrients influence tumor growth and cancer treatment. It fully focuses on matching specific diets with tumor genotypes and treatment regimens to improve the outcomes of cancer therapy. The company was founded to translate breakthrough discoveries, made by cancer research laboratories, into clinical practice. Its founding team includes some of the industry’s preeminent researchers and clinicians.

Marigold Health

Series A in 2024
Marigold Health uses AI-augmented chat support groups to reach and retain patients with behavioral health needs in community-based treatment. Patients receive a personalized wraparound support while care teams see dramatic gains in capacity using patients to engage each other. We partner directly with treatment providers and managed care organizations in the Medicaid market.

Tierra Biosciences

Seed Round in 2018
Tierra Biosciences develops cell free technologies that enables the discovery of molecules that are difficult to produce in common types of laboratory cells. The company’s technology uses automation, computation, and high throughput cell-free expression for expressing DNA from a variety of microbial sources. Tierra Biosciences’ Next Generation Expression platform allows for high-throughput data collection that is real and experimentally validated at speeds of simulation-based approaches. Tierra Biosciences was formerly known as Synvitrobio, Inc and changed its name to Tierra Biosciences in September 2018. Tierra Biosciences was founded in 2015 and is headquartered in San Francisco, California.

Azitra

Series A in 2019
Azitra is a clinical-stage medical dermatology company that leverages extensive scientific knowledge about the skin microbiome to discover and develop novel products for the treatment of adverse skin conditions and diseases.The Company’s technology platform, developed in collaboration with scientists at Yale University and the Jackson Laboratory, is based on a proprietary strain of the natural commensal bacteria Staphylococcus epidermidis.

Solugen

Private Placement in 2019
Solugen is a specialty chemicals ​manufacturer creating chemistries that are safe, cost-effective, and environmentally-friendly. The company manufactures and supplies of registered biocides and specialty bio-based solutions for divalent control in process flow assurance and asset integrity. Solugen's patented approach takes advantage of bio-inspired reactions to use plant material as a low-cost feedstock to produce novel products cost-competitive with the competition.

Checkerspot

Private Placement in 2019
Checkerspot, Inc., a biotech company, produces performance materials using microalgae. The company was founded in 2016 and is based in Berkeley, California.

54gene

Private Placement in 2019
54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Xilis

Series A in 2021
Xilis, Inc. develops next generation organoid technologies to guide precision therapy for cancer patients and improve drug discovery. It offers The XilisµO, a platform that enables rapid diagnostics, personalized drug screening, and scalable patient-derived models for high-throughput drug discovery. Xilis, Inc. was founded in 2019 and is based in Chapel Hill, North Carolina.